Difesa Capital Management, LP Cellectar Biosciences, Inc. Put Options Transaction History

Difesa Capital Management, LP

  • $0
  • Q4 2023

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

About Cellectar Biosciences, Inc.

CLRB Quotes by TradingView
  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $12.4M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Difesa Capital Management, LP Portfolio

Follow Difesa Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Difesa Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Difesa Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email